<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272686</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0096</org_study_id>
    <secondary_id>NCI-2015-00843</secondary_id>
    <nct_id>NCT02272686</nct_id>
  </id_info>
  <brief_title>Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma</brief_title>
  <official_title>Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in &quot;Double-Hit&quot; B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if ibrutinib can help to control&#xD;
      lymphoma in patients who have had an autologous stem cell transplant (a transplant using your&#xD;
      own stem cells). The safety of this drug will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:&#xD;
&#xD;
      If you take part in this study, you will take ibrutinib by mouth 1 time each day for up to 3&#xD;
      years. You must swallow the capsules whole with a glass (about 8 ounces) of water. Do not&#xD;
      open, break, or chew the capsules. You should take ibrutinib at the same time every day.&#xD;
&#xD;
      If you miss a dose of ibrutinib, take it as soon as you remember on the same day. Take your&#xD;
      next dose of ibrutinib at your regular time on the next day. Do not take 2 doses of ibrutinib&#xD;
      on the same day to make up for a missed dose.&#xD;
&#xD;
      You will be given a study drug diary to write down what time you take each dose of ibrutinib.&#xD;
      You need to bring the study drug diary, any leftover study drug, and any empty study drug&#xD;
      containers with you to each visit.&#xD;
&#xD;
      The dose of ibrutinib you receive may be lowered, if the doctor thinks it is needed.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      One (1) time during Weeks 1-4, 6, and 8 and then 1 time each month after that for up to 3&#xD;
      years after your first dose of ibrutinib, blood (about 2 tablespoons) will be drawn for&#xD;
      routine tests and to check your kidney and liver function. The blood draws may be performed&#xD;
      at MD Anderson or at a lab closer to your home.&#xD;
&#xD;
      If the study doctor thinks it is needed, you may need to have these blood draws more often.&#xD;
&#xD;
      Around 1 month after your first dose of ibrutinib, you will have a bone marrow&#xD;
      biopsy/aspirate to check the status of the disease, if the study doctor thinks it is needed.&#xD;
      To collect a bone marrow biopsy/aspirate, an area of the hip or other site is numbed with&#xD;
      anesthetic, and a small amount of bone and bone marrow is withdrawn through a large needle.&#xD;
&#xD;
      Around 3, 6, 9, and 12 months, then every 6 months for 3 years after your first dose of&#xD;
      ibrutinib:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  You will have computed tomography (CT) scans to check the status of the disease.&#xD;
&#xD;
        -  You will have a bone marrow biopsy/aspirate to check the status of the disease.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for up to 3 years. You will no longer be able to take&#xD;
      the study drug if the disease gets worse, if intolerable side effects occur, or if you are&#xD;
      unable to follow study directions.&#xD;
&#xD;
      Your participation on this study will be over after about 3 years.&#xD;
&#xD;
      Follow-Up Visit:&#xD;
&#xD;
      You will continue to have the CT scans and blood draws described in the study visits section&#xD;
      1 time a year for up to 3 years.&#xD;
&#xD;
      If you had a positron emission tomography (PET) scan that was performed at the time of your&#xD;
      transplant and the scan showed that the disease was still in your body, you will have a PET&#xD;
      scan 1 time each year while taking ibrutinib. The PET scan will not be repeated if the&#xD;
      results show that there is no disease in the body.&#xD;
&#xD;
      This is an investigational study. Ibrutinib is FDA-approved and commercially available for&#xD;
      the treatment of many types of cancers, including mantle cell lymphoma with 1 prior therapy.&#xD;
      The use of ibrutinib to treat double hit lymphoma after an autologous stem cell transplant is&#xD;
      considered investigational. The study doctor can explain how the study drug is designed to&#xD;
      work.&#xD;
&#xD;
      Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 3, 2016</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Two years</time_frame>
    <description>Participants will be assessed for disease status and survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Three Years</time_frame>
    <description>Participants will be assessed at 3 year time point for survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>560 mg by mouth daily.</description>
    <arm_group_label>Ibrutinib</arm_group_label>
    <other_name>PCI-32765</other_name>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly diagnosed double hit in first complete remission, anytime during&#xD;
             the first 3 months after chemoimmunotherapy followed by autologous stem cell&#xD;
             transplantation if there was no evidence of progression.&#xD;
&#xD;
          2. Double hit lymphoma is defined as B-cell lymphoma with genetic abnormalities involving&#xD;
             A) and in addition, B) and/or C): A) C-MYC arrangement or amplification by FISH study.&#xD;
             B) BCL2 rearrangement or amplification by FISH study. C) BCL6 rearrangement or&#xD;
             amplification by FISH study.&#xD;
&#xD;
          3. ANC &gt;/= 1,000, platelets &gt;/= 75,000.&#xD;
&#xD;
          4. AST and/or ALT &lt; 3 times the ULN.&#xD;
&#xD;
          5. Creatinine clearance &gt; 30 ml/min (Cockcroft-Gault formula using ideal body weight).&#xD;
&#xD;
          6. Male or female age &gt;/= 18 years.&#xD;
&#xD;
          7. ECOG performance status &lt;/= 2.&#xD;
&#xD;
          8. Willing and able to participate in all required evaluations and procedures in this&#xD;
             study protocol including swallowing capsules without difficulty.&#xD;
&#xD;
          9. Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information.&#xD;
&#xD;
         10. Patient should preferably have received a pre-transplant conditioning with rituximab&#xD;
             and Carmustine/Etoposide/Cytarabine/Melphalan/Rituxan (BEAM/R) . Other regimens which&#xD;
             are similar may be accepted at the discretion of the PI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy within 3 weeks, nitrosoureas (carmustine) within 6 weeks,&#xD;
             therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates&#xD;
             within 10 weeks, radiation therapy within 3 weeks, or major surgery within 2 weeks of&#xD;
             first dose of study drug.&#xD;
&#xD;
          2. Relapsed within three months post transplant.&#xD;
&#xD;
          3. History of other malignancies within the past year except for treated basal cell or&#xD;
             squamous cell skin cancer or in situ cervical cancer.&#xD;
&#xD;
          4. Known CNS lymphoma.&#xD;
&#xD;
          5. Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or any Class 3 (moderate) or 4 (severe) cardiac disease as defined by the&#xD;
             New York Heart Association Functional Classification.&#xD;
&#xD;
          6. Requires treatment with a strong cytochrome P450 (CYP)3A inhibitor (i.e. Voriconazole,&#xD;
             posaconazole, itraconazole, clarithromycin, etc.) or inducer (carbamazepine, rifampin,&#xD;
             phenytoin, etc.).&#xD;
&#xD;
          7. AST and/or ALT &gt;/= 3 times the ULN.&#xD;
&#xD;
          8. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel or symptomatic ulcerative colitis, symptomatic&#xD;
             inflammatory bowel disease, or partial or complete bowel obstruction.&#xD;
&#xD;
          9. Known history of human immunodeficiency virus or active infection with hepatitis C&#xD;
             virus or hepatitis B virus or any uncontrolled active systemic infection.&#xD;
&#xD;
         10. Positive pregnancy test in women of childbearing potential.&#xD;
&#xD;
         11. Lactating or pregnant or will not agree to use contraception during the study and for&#xD;
             30 days after the last dose of study drug if sexually active and able to bear&#xD;
             children.&#xD;
&#xD;
         12. Concomitant use of warfarin or other Vitamin K antagonists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>November 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Blood And Marrow Transplantation</keyword>
  <keyword>Post Autologous Stem Cell Transplantation</keyword>
  <keyword>SCT</keyword>
  <keyword>B-cell lymphoma</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>PCI-32765</keyword>
  <keyword>Imbruvica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02272686/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 6/3/2016 to 2/21/2017.</recruitment_details>
      <pre_assignment_details>Ibrutinib maintenance will not be started if patient relapses post transplant</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibrutinib Maintenance</title>
          <description>Ibrutinib maintenance after autologous stem cell transplantation (SCT) in double-hit lymphoma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibrutinib Maintenance</title>
          <description>Ibrutinib maintenance after autologous stem cell transplantation (SCT) in double-hit lymphoma</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS)</title>
        <description>Participants will be assessed for disease status and survival.</description>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib Maintenance</title>
            <description>Ibrutinib maintenance after autologous stem cell transplantation (SCT) in double-hit lymphoma</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS)</title>
          <description>Participants will be assessed for disease status and survival.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Participants will be assessed at 3 year time point for survival.</description>
        <time_frame>Three Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib Maintenance</title>
            <description>Ibrutinib maintenance after autologous stem cell transplantation (SCT) in double-hit lymphoma</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Participants will be assessed at 3 year time point for survival.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an average of 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibrutinib Maintenance</title>
          <description>Ibrutinib maintenance after autologous stem cell transplantation (SCT) in double-hit lymphoma</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa F. Khouri, MD, Professor, Stem Cell Transplantation</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-0049</phone>
      <email>ikhouri@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

